From Bench to Clinic: the Potential of Therapeutic Targeting of the IL-22 Signaling Pathway in Atopic Dermatitis

키워드

참고문헌 (82)

1. "Patient perspectives: atopic dermatitis (eczema)", Pediatr Dermatol, 33, pp.85~86 (2016)
2. Bieber T, "Global Allergy Forum and 3rd Davos Declaration 2015: atopic dermatitis", eczema: challenges and opportunities toward precision medicine, 2016, pp.71, 588~592
3. Flohr C, "New insights into the epidemiology of childhood atopic dermatitis", Allergy, 69, pp.3~16 (2014)
4. Leung DY, "Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches", J Allergy Clin Immunol, 134, pp.769~779 (2014)
5. Brunner PM, "The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies", J Allergy Clin Immunol, 139, pp.S65~S76 (2017)
6. Mansouri Y, "Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics", J Clin Med, 4, pp.858~873 (2015)
7. Noda S, "The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization", J Allergy Clin Immunol, 136, pp.1254~1264 (2015)
8. Brunner PM, "Early-onset pediatric atopic dermatitis is characterized by TH2", TH17, J Allergy Clin Immunol, pp.2018, 141[DOI]
9. Esaki H, "Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin", J Allergy Clin Immunol, 138, pp.1639~1651 (2016)
10. Ouyang W, "Regulation and functions of the IL-10 family of cytokines in inflammation and disease", Annu Rev Immunol, 29, pp.71~109 (2011)
11. Rutz S, "The IL-20 subfamily of cytokines--from host defence to tissue homeostasis", Nat Rev Immunol, 14, pp.783~795 (2014)
12. Cella M, "A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity", Nature, 457, pp.722~725 (2009)
13. Sonnenberg GF, "Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22", Nat Immunol, 12, pp.383~390 (2011)
14. Lee JS, "AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch", Nat Immunol, 13, pp.144~151 (2011)
15. Duhen T, "Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells", Nat Immunol, 10, pp.857~863 (2009)
16. Trifari S, "Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells", Nat Immunol, 10, pp.864~871 (2009)
17. Kotenko SV, "Identification and functional characterization of a second chain of the interleukin-10 receptor complex", EMBO J, 16, pp.5894~5903 (1997)
18. Kotenko SV, "Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity", J Immunol, 166, pp.7096~7103 (2001)
19. Wolk K, "IL-22 increases the innate immunity of tissues", Immunity, 21, pp.241~254 (2004)
20. Wolk K, "Biology of interleukin-22", Semin Immunopathol, 32, pp.17~31 (2010)
21. Kronenberger B, "Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study", BMC Med, 10, pp.102~ (2012)
22. Lindemans CA, "Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration", Nature, 528, pp.560~564 (2015)
23. Kim Y, "The pathogenic role of interleukin-22 and its receptor during UVB-induced skin inflammation", PLoS One, 12, pp.e0178567~ (2017)
24. Fukaya T, "Pivotal role of IL-22 binding protein in the epithelial autoregulation of interleukin-22 signaling in the control of skin inflammation", Front Immunol, 9, pp.1418~ (2018)
25. Boniface K, "A role for T cell-derived interleukin 22 in psoriatic skin inflammation", Clin Exp Immunol, 150, pp.407~415 (2007)
26. Fujita H., "The role of IL-22 and Th22 cells in human skin diseases", J Dermatol Sci, 72, pp.3~8 (2013)
27. Zhang W, "The pro-inflammatory cytokine IL-22 up-regulates keratin 17 expression in keratinocytes via STAT3 and ERK1", 2, 2012, pp.7, e40797~
28. Boniface K, "IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes", J Immunol, 174, pp.3695~3702 (2005)
29. Sa SM, "The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis", J Immunol, 178, pp.2229~2240 (2007)
30. Guttman-Yassky E, "Low expression of the IL-23", Th17 pathway in atopic dermatitis compared to psoriasis, 2008, pp.181, 7420~7427
31. Nograles KE, "IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells", J Allergy Clin Immunol, 123, pp.1244.e2~1252.e2 (2009)
32. Gittler JK, "Progressive activation of TH2", TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis, 2012, pp.130, 1344~1354
33. Hayashida S, "Significant correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis", J Dermatol Sci, 61, pp.78~79 (2011)
34. Meephansan J, "Effect of methotrexate on serum levels of IL-22 in patients with psoriasis", Eur J Dermatol, 21, pp.501~504 (2011)
35. Yoon J, "IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization", J Exp Med, 213, pp.2147~2166 (2016)
36. Di Meglio P, "The multitasking organ: recent insights into skin immune function", Immunity, 35, pp.857~869 (2011)
37. Bos JD, "The skin immune system its cellular constituents and their interactions", Immunol Today, 7, pp.235~240 (1986)
38. Leung DY, "New insights into atopic dermatitis", J Clin Invest, 113, pp.651~657 (2004)
39. Boguniewicz M, "Atopic dermatitis: a disease of altered skin barrier and immune dysregulation", Immunol Rev, 242, pp.233~246 (2011)
40. Spergel JM, "Atopic dermatitis and the atopic march", J Allergy Clin Immunol, 112, pp.S118~S127 (2003)
41. von Kobyletzki LB, "Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort", BMC Dermatol, 12, pp.11~ (2012)
42. Bantz SK, "The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma", J Clin Cell Immunol, 5, pp.202~ (2014)
43. Tao Zheng, "The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma", Allergy, Asthma & Immunology Research, 3(2), pp.67~73 (2011), 대한천식알레르기학회
44. Gustafsson D, "Development of allergies and asthma in infants and young children with atopic dermatitis--a prospective follow-up to 7 years of age", Allergy, 55, pp.240~245 (2000)
45. Oyoshi MK, "Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation", Immunity, 37, pp.747~758 (2012)
46. He R, "TSLP acts on infiltrating effector T cells to drive allergic skin inflammation", Proc Natl Acad Sci U S A, 105, pp.11875~11880 (2008)
47. Oyoshi MK, "Mechanical injury polarizes skin dendritic cells to elicit a TH2 response by inducing cutaneous thymic stromal lymphopoietin expression", J Allergy Clin Immunol, 126, pp.976~984 (2010)
48. He R, "Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge", Proc Natl Acad Sci U S A, 104, pp.15817~15822 (2007)
49. He R, "Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13", J Allergy Clin Immunol, 124, pp.761.e1~770.e1 (2009)
50. Juan Manuel Leyva-Castillo, "IL-22 promotes allergic airway inflammation in epicutaneously sensitized mice", Journal of Allergy and Clinical Immunology, 143(2), pp.619~630.e7 (2019), Elsevier BV[DOI]
51. Galand C, "IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells", J Allergy Clin Immunol, 138, pp.1356~1366 (2016)
52. Bartnikas LM, "Epicutaneous sensitization results in IgE-dependent intestinal mast cell expansion and food-induced anaphylaxis", J Allergy Clin Immunol, 131, pp.451e1-6~460e1-6 (2013)
53. Spergel JM, "Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice", J Clin Invest, 101, pp.1614~1622 (1998)
54. Gurney AL., "IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues", Int Immunopharmacol, 4, pp.669~677 (2004)
55. Liang SC, "Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides", J Exp Med, 203, pp.2271~2279 (2006)
56. Scriba TJ, "Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response", J Immunol, 180, pp.1962~1970 (2008)
57. Eyerich S, "Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling", J Clin Invest, 119, pp.3573~3585 (2009)
58. Teraki Y, "IL-13", IL-22-coproducing T cells, a novel subset, are increased in atopic dermatitis, 2013, pp.132, 971~974
59. Akdis M, "TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection", J Allergy Clin Immunol, 129, pp.1438~1449 (2012)
60. Patrick M. Brunner, "Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab", Journal of Allergy and Clinical Immunology, 143(1), pp.142~154 (2019), Elsevier BV[DOI]
61. Guttman-Yassky E, "Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial", J Am Acad Dermatol, 78, pp.872.e6~881.e6 (2018)
62. Fujita H, "Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production", Proc Natl Acad Sci U S A, 106, pp.21795~21800 (2009)
63. Korenfeld D, "A type of human skin dendritic cell marked by CD5 is associated with the development of inflammatory skin disease", JCI Insight, 2, pp.e96101~ (2017)
64. Kim JH, "CD1a on Langerhans cells controls inflammatory skin disease", Nat Immunol, 17, pp.1159~1166 (2016)
65. Soumelis V, "Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP", Nat Immunol, 3, pp.673~680 (2002)
66. Andersen CJ, "Impact of obesity and metabolic syndrome on immunity", Adv Nutr, 7, pp.66~75 (2016)
67. Rank MA, "IL-33-activated dendritic cells induce an atypical TH2-type response", J Allergy Clin Immunol, 123, pp.1047~1054 (2009)
68. Hedrick MN, "CCR6 as a possible therapeutic target in psoriasis", Expert Opin Ther Targets, 14, pp.911~922 (2010)
69. Zhao B, "CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor", Toxicol Sci, 117, pp.393~403 (2010)
70. Paller AS, "Therapeutic pipeline for atopic dermatitis: End of the drought?", J Allergy Clin Immunol, 140, pp.633~643 (2017)
71. Weidinger S, "Atopic dermatitis", Nat Rev Dis Primers, 4, pp.1~ (2018)
72. Bissonnette R, "Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial", Br J Dermatol, 175, pp.902~911 (2016)
73. Emma Guttman-Yassky, "Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study", Journal of the American Academy of Dermatology, 80(4), pp.913~921.e9 (2019), Elsevier BV[DOI]
74. Gooderham MJ, "Dupilumab: A review of its use in the treatment of atopic dermatitis", J Am Acad Dermatol, 78, pp.S28~S36 (2018)
75. Hajdarbegovic E, "Anti-interleukin-31 receptor a antibody for atopic dermatitis", N Engl J Med, 376, pp.2092~2093 (2017)
76. Kabashima K, "Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study", J Allergy Clin Immunol, 142, pp.1121.e7~1130.e7 (2018)
77. Kahn J, "JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases", Semin Cutan Med Surg, 37, pp.198~208 (2018)
78. Damsky W, "JAK inhibitors in dermatology: the promise of a new drug class", J Am Acad Dermatol, 76, pp.736~744 (2017)
79. Ko K, "Discovery of a novel highly selective histamine H4 receptor antagonist for the treatment of atopic dermatitis", J Med Chem, 61, pp.2949~2961 (2018)
80. Rossbach K, "Histamine H4 receptor knockout mice display reduced inflammation in a chronic model of atopic dermatitis", Allergy, 71, pp.189~197 (2016)
81. Ehling S, "Allergic inflammation is augmented via histamine H4 receptor activation: the role of natural killer cells in vitro and in vivo", J Dermatol Sci, 83, pp.106~115 (2016)
82. Vakharia PP, "New therapies for atopic dermatitis: additional treatment classes", J Am Acad Dermatol, 78, pp.S76~S83 (2018)

관련 논문AI추천